A Two-part Protein to Treat Uveal Melanoma
The FDA approved the targeted immunotherapy tebentafusp-tebn for certain adult patients with uveal melanoma. The U.S. Food and Drug Administration (FDA) has approved tebentafusp-tebn (Kimmtrak), a fusion protein that acts as an immunotherapy, for...